Vogenx

Lookout
Welcome to
VOGENX

Improving the lives of patients suffering from dysfunctions in human metabolism and rare disease.

Lookout
Welcome to
VOGENX

Improving the lives of patients suffering from dysfunctions in human metabolism and rare disease.

previous arrow
next arrow

Our Company

Post Bariatric Hypoglycemia

Developing Novel Therapeutics for Metabolic and Gastrointestinal Disease

Vogenx is a clinical stage life science and drug development company focused on the development of mizagliflozin for the treatment of post bariatric hypoglycemia (PBH) and gastroparesis. Mizagliflozin is a small molecule inhibitor of sodium glucose transporter 1 (SGLT1) with a site of action in the intestinal lumen. 

PBH and gastroparesis are conditions with growing high unmet medical need and either no or limited approved therapeutic treatments.

Transforming the lives of Patients with Post Bariatric Hypoglycemia

PBH is a form of reactive hypoglycemia that usually presents 6 months to 4 years post-surgery. PBH related hypoglycemic events typically occur 1-2 hours after a meal and are commonly caused by rapid increases in postprandial circulating glucose and a corresponding uncontrolled spike in insulin.

This disease presents on a spectrum with patients experiencing symptoms characterized within a wide range of mild, moderate and severe PBH. Symptoms can include those associated with neuroglycopenia such as weakness, drowsiness,  dizziness, confusion, seizure and loss of consciousness that can dangerously impair normal day-to-day activities and can sometimes be life-threatening. 

The graphs below compare levels of circulating blood glucose and insulin after a mixed meal tolerance test in normal healthy subjects that have not had bariatric surgery, non-PBH bariatric surgery patients, and patients diagnosed with PBH. Healthy patients that have not undergone bariatric surgery in the Control group (blue line) exhibit a normal increase, plateau, and gradual return to normal level of circulating blood glucose and insulin. Bariatric surgery patients that do not have PBH, indicated as Asymptomatic-RYGB (green line) typically experience rapid absorption and elevated levels of circulating glucose. In response, these patient’s body’s secret an elevated, yet moderately controlled increase in insulin coupled with an accelerated return to normal fasting levels when compared to Control. These patients may experience certain symptoms associated with PBH but have not been formally diagnosed with PBH. Patients diagnosed with PBH, represented below as PBH-RYGB (red line), typically demonstrate the same rapid increase in glucose absorption, but their corresponding secretion of insulin is uncontrolled, leading to postprandial hypoglycemic events.  

Post bariatric surgery patients, with and without PBH, experience pronounced increases in postprandial blood glucose and insulin compared control. Blue line: Control (healthy subjects); Green line: Asymptomatic-RYGB (Patients that have had RYGB bariatric surgery but do not have PBH; Red line: PBH-RYGB (Patients that have had RYGB bariatric surgery and have been diagnosed with PBH). Reference: Salehi M, Gastaldelli A, D’alessio DA. Altered islet function and insulin clearance cause hyperinsulinemia in gastric bypass patients with symptoms of postprandial hypoglycemia. The Journal of Clinical Endocrinology & Metabolism. 2014 Jun; 99(6): 2008-17.

Post bariatric surgery patients, with and without PBH, experience pronounced increases in postprandial blood glucose and insulin compared control.
Blue line: Control (healthy subjects); Green line: Asymptomatic-RYGB (Patients that have had RYGB bariatric surgery but do not have PBH; Red line: PBH-RYGB (Patients that have had RYGB bariatric surgery and have been diagnosed with PBH).
Reference: Salehi M, Gastaldelli A, D’alessio DA. Altered islet function and insulin clearance cause hyperinsulinemia in gastric bypass patients with symptoms of postprandial hypoglycemia. The Journal of Clinical Endocrinology & Metabolism. 2014 Jun; 99(6):
2008-17.

Clinical Trials

Experienced professionals

R&D Locations

State-of-the-art technology

Product Pipeline

Sampling at your address

Medical Innovation

Advice and Recommendations

Transforming lives of Patients with rare Disease

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Services

Research Technologies

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Immunology

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Infectious Diseases

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Inflammatory Bowel Diseases

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Neuroscience and Rare Diseases

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Cardiovascular and Metabolism

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

The Science Behind MIZAGLIFLOZIN

After bariatric surgery, most patients experience significant weight loss that is associated with improved insulin sensitivity and concomitant improvement in glucose homeostasis. However, some patients (usually 6 months to 4 years post-surgery) begin to experience PBH, characterized by reactive hypoglycemia that occurs 1-2 hours after a meal. While the exact cellular and molecular events leading to this sudden drop in blood glucose are unclear, the hypoglycemia is preceded by a rapid absorption of glucose from the intestine leading to an uncommon spike in blood glucose which stimulates release of a correspondingly high level of insulin from the pancreatic β-cells.

SGLT1 is responsible for the uptake of glucose from the intestine following a meal. Mizagliflozin is a potent and selective inhibitor of SGLT1. Mizagliflozin is also minimally absorbed and therefore inhibits SGLT1 with a site of action that is localized on the luminal side of the intestine, thereby reducing risks associated with off-target activity. By inhibiting SGLT1 in the intestine there is a delay in the absorption of glucose into the blood, as well as a reduction in the total amount of glucose absorbed, thus reducing the effect of glucose on insulin secretion which may prevent hypoglycemic events. In nonclinical and clinical studies in healthy human subjects, treatment with mizagliflozin resulted in decreases in postprandial plasma glucose and insulin.

In addition to its primary role in mediating glucose absorption in the intestine, decreased SGLT1 activity has also been associated with overall improved health. In one long-term study, human subjects with genetic variants in the SGLT1 gene that led to reduced SGLT1 function were tracked for 25 years. These subjects displayed reduced intestinal glucose absorption during oral glucose tolerance tests, reduced incidence of diagnosed diabetes, and reduced risk of death or heart failure. These data suggest that SGLT1 function influences metabolic disease risk related to carbohydrate intake, and selective SGLT1 inhibitors could be useful in reducing the risk of metabolic disease and cardiovascular consequences (Seidelmann et al. JACC 2018; 72: 1763-73).

Why Choose Us

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

The Science Behind VogenX Novel Therapeutics

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Treatments for Unmet Needs

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

High-End Technology

Lorem ipsum dolor sit ame

Safe Diagnoses

Lorem ipsum dolor sit ame

For More Information

Testimonials

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Name Designation

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Name Designation

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Name Designation

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Name Designation

Health Check Packs

Basic Care

$90
  • Complete Blood Count
  • Liver Function Blood Test
  • Heart Disease Blood Tests
  • Cholesterol / Lipid Levels
  • Sexually Transmitted Diseases
  • Male / Female General Health Panel
  • Comprehensive Metabolic Panel

Essential Care

$190
  • Complete Blood Count
  • Liver Function Blood Test
  • Heart Disease Blood Tests
  • Cholesterol / Lipid Levels
  • Sexually Transmitted Diseases
  • Male / Female General Health Panel
  • Comprehensive Metabolic Panel

Total Care

$290
  • Complete Blood Count
  • Liver Function Blood Test
  • Heart Disease Blood Tests
  • Cholesterol / Lipid Levels
  • Sexually Transmitted Diseases
  • Male / Female General Health Panel
  • Comprehensive Metabolic Panel